ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
128.957,09
2,64%
S&P 500
5.638,94
2,13%
US Dollar vs BRL
5,7446
0,00%
Bitcoin
84.317,48
0,43%
Brent Oil
70,285
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. RAPT Therapeutics Inc (RAPT)

  7. RAPT Therapeutics Inc (RAPT) Notícias

RAPT

RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RAPT
DataHoraFonteTítuloCódigoCompanhia
07/03/202518:30GlobeNewswire Inc.RAPT Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:RAPTRAPT Therapeutics Inc
06/03/202511:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
06/03/202510:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
06/03/202510:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
06/03/202510:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
28/01/202509:35Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RAPTRAPT Therapeutics Inc
28/01/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RAPTRAPT Therapeutics Inc
21/01/202518:58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
09/01/202510:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
06/01/202520:38Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RAPTRAPT Therapeutics Inc
06/01/202510:00GlobeNewswire Inc.RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsNASDAQ:RAPTRAPT Therapeutics Inc
03/01/202516:08Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202409:10GlobeNewswire Inc.RAPT Therapeutics Announces $150 Million Private PlacementNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202409:00GlobeNewswire Inc.RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyNASDAQ:RAPTRAPT Therapeutics Inc
14/11/202411:39Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
12/11/202410:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
11/11/202410:00GlobeNewswire Inc.Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNASDAQ:RAPTRAPT Therapeutics Inc
08/08/202409:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
08/08/202409:00GlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
23/05/202419:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202409:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202413:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202410:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202418:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202409:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202410:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202410:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202410:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202410:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202310:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RAPT

Seu Histórico Recente

TSXV
RHC
Royal Helium
BIT
NSCIT4000393
Finland
LSE
93AT
Warwick Ca49
FTSE
NMX351020
FTSE 350 Real Estate Inv...
BIT
NSCIT2287877
European Investment Bank...
NASDAQI
B4020GI
OMX Baltic Consumer Prod...
TSX
PDC
Invesco Canadian Dividen...
LATK
FUFUUSDT
FUFU
EU
ALGRO
Grolleau
BITMOT
3013845
Sunny Spv 2 Fr Eur3m+2% ...
BTRX
PROMUSDT
Token Prometeus Network
LSE
RRR
Red Rock Resources
ASX
PBH
Pointsbet
BIT
NSCIT5503411
Centro di riabilitazione...
LSE
CES1
Ishr Msci Emusc
ASX
EMP
Emperor Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios